COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF GASTROINTESTINAL DISEASES

• US 20160206564A1
• Filed: 09/22/2014
• Published: 07/21/2016
• Est. Priority Date: 09/27/2013
• Status: Abandoned Application

• Current Assignee: Ira Milton Trachtman
• Original Assignee: Ira Milton Trachtman
• Inventors: TRACHTMAN, Ira Milton
• Application Number:
  US15/025,377
• Publication Number:
  US 20160206564A1
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61K 2035/115 Probiotics
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/202 having three or more double bonds, e.g. linolenic eicosanoids, e.g. leukotrienes A61K31/557
• CPC Class Codes: A61K 31/437 the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• CPC Class Codes: A61K 31/451 having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
• CPC Class Codes: A61K 31/606 having amino groups
• CPC Class Codes: A61K 35/741 Probiotics probiotic yeast, e.g. saccharomyces A61K36/06
• CPC Class Codes: A61K 35/742 Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• CPC Class Codes: A61K 35/745 Bifidobacteria
• CPC Class Codes: A61K 35/747 Lactobacilli, e.g. L. acidophilus or L. brevis
• CPC Class Codes: A61K 36/064 Saccharomycetales, e.g. baker's yeast
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/209 containing drug in at least two layers or in the core and in at least one outer layer
• CPC Class Codes: A61K 9/5084 Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs tablets containing such a mixture A61K9/2077
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system

Abstract

Methods and compositions for treating inflammatory bowel disease, irritable bowel syndrome, and travelers'"'"' diarrhea involve the use of targeted antibiotics in combination with probiotic formulations. The probiotics mitigate many of the deleterious side effects associated with antibiotic use and permit the antibiotic to be administered at a higher dose and for a longer duration than would otherwise be possible in the absence of the probiotic. The practice of the invention may reduce or eliminate the use of immunosuppressants and other drugs in the treatment and management of inflammatory bowel disease, irritable bowel syndrome, travelers'"'"' diarrhea, and hepatic encephalopathy.

Claims

1-74. -74. (canceled)

75. An oral dosage form comprising:

(i) a delayed-release component comprising rifaximin; and

(ii) an immediate-release component comprising a probiotic formulation in an amount effective to restore normal microflora colonies in the gut, said probiotic formulation including at least one strain selected from the group consisting of Bifidobacterium bifidum;

Bifidobacterium breve;

Bifidobacterium infantis;

Bifidobacterium longum;

Lactobacillus acidophilus;

Lactobacillus bulgaricus;

Lactobacillus paracasein;

Saccharomyces boulardii, and combinations thereof;

wherein said immediate-release component releases said probiotic formulation upon contact with fluid in the stomach; and

wherein said delayed release component releases said antibiotic at a pH of 7 or greater.

76. The oral dosage form according to claim 75, wherein said antibiotic comprises from about 100 mg to about 500 mg of rifaximin and wherein said probiotic formulation includes at least about 20 billion live cells.

77. The oral dosage form according to claim 75, wherein said delayed-release component comprises microcapsules of an enteric coating polymer that dissolves at a pH of 7 or greater.

78. The oral dosage form according to claim 75, wherein said probiotic formulation includes Bifidobacterium bifidum.

79. The oral dosage form according to claim 75, wherein said probiotic formulation includes Bifidobacterium breve.

80. The oral dosage form according to claim 75, wherein said probiotic formulation includes Bifidobacterium infantis.

81. The oral dosage form according to claim 75, wherein said probiotic formulation includes Bifidobacterium longum.

82. The oral dosage form according to claim 75, wherein said probiotic formulation includes Saccharomyces boulardii.

83. The oral dosage form according to claim 75, wherein said probiotic formulation includes Lactobacillus acidophilus.

84. The oral dosage form according to claim 75, wherein said probiotic formulation includes Lactobacillus bulgaricus.

85. The oral dosage form according to claim 75, wherein said probiotic formulation includes Lactobacillus paracasein.

86. A method for the treatment or prophylaxis of irritable bowel syndrome due to bacterial infection comprising administering daily for a duration effective to reduce or substantially eliminate colonization of pathogenic bacteria in the gastrointestinal tract, a composition comprising:

an amount of an antibiotic effective to reduce colonization of pathogenic bacteria in the gastrointestinal tract, said antibiotic comprising rifaximin, and

a probiotic formulation in an amount effective to restore normal microflora colonies in the gut, said probiotic formulation including at least one strain selected from the group consisting of Arthrobacter agilis, Arthrobacter citreus, Arthrobacter globiformis, Arthrobacter leuteus, Arthrobacter simplex, Azotobacter chroococcum, Azotobacter paspali, Azospirillum brasiliencise, Azospriliium lipoferum, Bacillus brevis, Bacillus macerans, Bacillus pumilus, Bacillus polymyxa, Bacillus subtilis, Bacteroides lipolyticum, Bacteroides succinogenes, Brevibacterium lipolyticum, Brevibacterium stationis, Bacillus laterosporus, Bacillus bifidum, Bacillus laterosporus, Bifidophilus infantis, Streptococcus thermophilous, Bifodophilus longum, Bifidobacteria animalis, Bifidobacteria bifidus, Bifidobacteria breve, Bifidobacteria longum, Kurtha zopfil, Lactobacillus paracasein, Lactobacillus acidophilus, Lactobacillus planetarium, Lactobacillus salivarius, Lactobacillus rueteri, Lactobacillus bulgaricus, Lactobacillus helveticus, Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus sporogenes, Lactococcus lactis, Myrothecium verrucaris, Pseudomonas calcis, Pseudomonas dentrificans, Pseudomonas flourescens, Pseudomonas glathei, Phanerochaete chrysosporium, Saccharomyces boulardii, Streptmyces fradiae, Streptomyces cellulosae, Stretpomyces griseoflavus, and combinations thereof.

87. The method according to claim 86, wherein said rifaximin is administered in a dose of about 275 to about 3,300 mg daily, and at least 20 billion live probiotic cells are administered daily.

88. The method according to claim 86, wherein at least 40 billion probiotic cells are administered daily, twice daily, or three time daily.

89. The method according to claim 86, wherein said treatment period is at least about 180 days.

90. The method according to claim 86, wherein said delayed-release component releases said antibiotic in the small intestine.

91. The method according to claim 90, wherein said delayed-release component releases said antibiotic primarily in the terminal ileum.

92. A method for the treatment or prophylaxis of travelers'"'"' diarrhea due to bacterial infection comprising administering daily, for an effective duration to reduce or substantially eliminate colonization of pathogenic bacteria in the gastrointestinal tract, a composition comprising:

an amount of an antibiotic effective to reduce colonization of pathogenic bacteria in the gastrointestinal tract, said antibiotic comprising rifaximin, and

a probiotic formulation in an amount effective to restore normal microflora colonies in the gut, said probiotic formulation including at least one strain selected from the group consisting of Arthrobacter agilis, Arthrobacter citreus, Arthrobacter globiformis, Arthrobacter leuteus, Arthrobacter simplex, Azotobacter chroococcum, Azotobacter paspali, Azospirillum brasiliencise, Azospriliium lipoferum, Bacillus brevis, Bacillus macerans, Bacillus pumilus, Bacillus polymyxa, Bacillus subtilis, Bacteroides lipolyticum, Bacteroides succinogenes, Brevibacterium lipolyticum, Brevibacterium stationis, Bacillus laterosporus, Bacillus bifidum, Bacillus laterosporus, Bifidophilus infantis, Streptococcus thermophilous, Bifodophilus longum, Bifidobacteria animalis, Bifidobacteria bifidus, Bifidobacteria breve, Bifidobacteria longum, Kurtha zopfil, Lactobacillus paracasein, Lactobacillus acidophilus, Lactobacillus planetarium, Lactobacillus salivarius, Lactobacillus rueteri, Lactobacillus bulgaricus, Lactobacillus helveticus, Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus sporogenes, Lactococcus lactis, Myrothecium verrucaris, Pseudomonas calcis, Pseudomonas dentrificans, Pseudomonas flourescens, Pseudomonas glathei, Phanerochaete chrysosporium, Saccharomyces boulardii, Streptmyces fradiae, Streptomyces cellulosae, Stretpomyces griseoflavus, and combinations thereof.

93. The method according to claim 92, wherein said delayed-release component releases said antibiotic in the small intestine.

94. The method according to claim 93, wherein said delayed-release component releases said antibiotic primarily in the terminal ileum.